Ipamorelin is a pentapeptide composed of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that belongs to the growth hormone secretagogue class of compounds. First developed in the 1990s by Novo Nordisk, it was initially investigated for potential therapeutic applications in growth hormone deficiency and related conditions.
Unlike GHRP-6 or GHRP-2, ipamorelin does not substantially increase appetite-stimulating ghrelin levels, nor does it cause significant elevations in cortisol, aldosterone, or prolactin at therapeutic doses.
Primary benefits include:
- Stimulation of natural growth hormone release
- Enhanced lipolysis and fat metabolism
- Improved muscle protein synthesis and recovery
- Increased bone mineral density
- Enhanced collagen production for skin and joint health
- Improved sleep architecture and quality
- Potential anti-aging and regenerative effects
What Is Ipamorelin?
Ipamorelin is a pentapeptide composed of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belonging to the growth hormone secretagogue (GHS) class of compounds. First developed in the 1990s by Novo Nordisk, it was initially investigated for potential therapeutic applications in growth hormone deficiency and related conditions.
Its defining characteristic is selectivity. Unlike earlier GHRPs such as GHRP-6 or GHRP-2, ipamorelin does not substantially increase appetite-stimulating ghrelin levels, nor does it cause significant elevations in cortisol, aldosterone, or prolactin at therapeutic doses. This selectivity profile has made it one of the most popular peptides in the growth hormone secretagogue class among researchers and clinicians exploring GH optimization.
How It Works
Ghrelin Receptor Activation
Ipamorelin functions as a ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHS-R1a) located in the hypothalamus and pituitary gland. This receptor activation triggers a signaling cascade that ultimately stimulates somatotroph cells in the anterior pituitary to synthesize and release growth hormone.
Unlike exogenous growth hormone administration, ipamorelin works within the body's natural feedback mechanisms. The pituitary gland releases GH in a pulsatile manner, and ipamorelin amplifies these natural pulses rather than creating a constant, supraphysiological elevation.
Selective Pituitary Stimulation
The selectivity of ipamorelin stems from its specific receptor binding profile. Research has demonstrated that ipamorelin does not significantly interact with receptors that would trigger cortisol release from the adrenal glands or prolactin secretion from lactotroph cells. This distinguishes it from less selective GHRPs that can produce meaningful increases in these hormones, which carry their own physiological consequences.
Synergy with Growth Hormone-Releasing Hormone
Ipamorelin's effects are potentiated when the hypothalamus releases endogenous growth hormone-releasing hormone (GHRH). The two pathways work synergistically — GHRH primes the pituitary while ipamorelin amplifies the release signal. This is why many protocols combine ipamorelin with synthetic GHRH analogs like CJC-1295 or Mod GRF 1-29 for enhanced effects.
IGF-1 Cascade
Following growth hormone release, the liver responds by producing insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic and regenerative effects throughout the body. Elevated IGF-1 promotes protein synthesis in muscle tissue, stimulates chondrocyte activity in cartilage, and enhances cellular repair mechanisms systemically.
Dosage Protocols
No FDA-approved dosing guidelines exist for ipamorelin. The following protocols are derived from clinical research and community reports:
- Standard range: 100-200 mcg per administration, with injections performed once or twice daily
- Most common protocol: 100-200 mcg administered once or twice daily — the bedtime dose is the most important, as it amplifies the natural nocturnal GH surge
Beginner Protocol
100 mcg once daily before bed, for 8-12 weeks. The bedtime dose capitalizes on the natural nocturnal GH surge and is the single most effective administration window.
Intermediate Protocol
100-200 mcg, twice daily (morning and before bed), for 8-12 weeks.
Advanced Protocol
200 mcg, two to three times daily, often combined with a GHRH analog such as CJC-1295, for 8-12 weeks.
Cycling Recommendations
Cycling is generally recommended, with 8-12 weeks on followed by 4-8 weeks off to prevent receptor desensitization and maintain pituitary sensitivity. The only published human trial used 7 days of continuous dosing; longer protocols are extrapolated from clinical rationale and community experience.
Timing Considerations
Administering ipamorelin on an empty stomach (at least 30 minutes before eating or 2 hours after) maximizes growth hormone release, as elevated blood glucose and insulin can blunt the GH response. The pre-bed dose capitalizes on the body's natural nocturnal GH surge.
How to Use / Administration Methods
Ipamorelin is administered via subcutaneous injection, typically into the abdominal fat, thigh, or deltoid region.
Injection process:
- Reconstitute the lyophilized powder with bacteriostatic water
- Draw the appropriate dose into an insulin syringe (typically 29-31 gauge)
- Pinch a fold of skin at the injection site
- Insert the needle at a 45-90 degree angle
- Slowly depress the plunger
- Withdraw and dispose of the needle properly
Injection sites should be rotated to prevent lipodystrophy or tissue irritation. Most users find subcutaneous abdominal injections the most convenient and least painful option.
Results Timelines
Weeks 1-2:
- Improved sleep quality and mild increases in energy
- Some users report more vivid dreams, correlating with enhanced REM sleep architecture
Weeks 3-4:
- Recovery from exercise improves noticeably
- Reduced muscle soreness and faster return to baseline after intense training sessions
Weeks 6-8:
- Body composition changes become more apparent, with gradual reductions in subcutaneous fat and improved muscle fullness
- Skin quality improvements, including increased hydration and reduced fine lines, may become noticeable
Weeks 10-12:
- More significant changes in body composition are typically observed
- Strength gains, improved joint comfort, and enhanced overall vitality commonly reported
Weeks 12-16+:
- Cumulative benefits reach their peak, with the most substantial improvements in body composition, recovery capacity, and anti-aging markers
- Hair and nail growth improvements are sometimes noted
Individual responses vary considerably based on age, baseline growth hormone levels, diet, exercise habits, and genetic factors.
Research Evidence
Pivotal Selectivity Study
A pivotal study published in the European Journal of Endocrinology established ipamorelin's selectivity, showing it released growth hormone in a dose-dependent manner without affecting ACTH, cortisol, prolactin, or thyroid-stimulating hormone levels — even at doses up to 100 mcg/kg.
Bone Health Research
Research in animal models has demonstrated ipamorelin's potential for improving bone health. Studies in aged female rats showed that ipamorelin administration increased bone mineral content and improved bone formation markers.
Post-operative Recovery
Investigation into post-operative recovery applications found that ipamorelin accelerated return of bowel function following abdominal surgery, suggesting potential therapeutic applications beyond body composition enhancement.
Comparative Analysis
A comparative study examining various GHRPs confirmed ipamorelin's superior selectivity profile, noting it produced the most specific GH release with minimal off-target hormonal effects among the compounds tested.
Stacking
Ipamorelin + CJC-1295 (no DAC) / Mod GRF 1-29
This is the most popular combination. The GHRH analog primes the pituitary while ipamorelin amplifies release, creating a synergistic effect that produces greater GH elevation than either peptide alone. Typical dosing involves equal amounts (e.g., 100 mcg of each) administered simultaneously.
Ipamorelin + BPC-157
For injury recovery and healing applications, some users combine ipamorelin's systemic regenerative effects with BPC-157's localized tissue repair properties.
Ipamorelin + Tesamorelin
This combination pairs ipamorelin with an FDA-approved GHRH analog, potentially offering enhanced fat reduction, particularly in the abdominal region.
When stacking, users typically maintain standard ipamorelin dosing while adding complementary peptides according to their individual protocols.
Reconstitution, Storage & Prep
Ipamorelin typically arrives as a lyophilized (freeze-dried) powder requiring reconstitution before use.
Reconstitution Process:
- Allow the peptide vial to reach room temperature
- Using a sterile syringe, draw the desired amount of bacteriostatic water (typically 2-3 mL per 5 mg vial)
- Inject the water slowly against the vial wall, allowing it to run down gently
- Swirl gently — never shake — until the powder is fully dissolved
- The solution should be clear and colorless
Dosing Calculation Example:
If reconstituting 5 mg with 2.5 mL bacteriostatic water, the concentration equals 2 mg/mL or 2000 mcg/mL. For a 200 mcg dose, draw 0.1 mL (10 units on a standard insulin syringe).
Storage Guidelines:
- Unreconstituted powder: Store at room temperature or refrigerated; stable for 12+ months
- Reconstituted solution: Refrigerate at 2-8°C (36-46°F); use within 4-6 weeks
- Never freeze reconstituted peptides
- Protect from light and heat
- Use bacteriostatic water (not sterile water) for multi-dose vials to prevent bacterial growth
Side Effects
Ipamorelin is generally well-tolerated, with most users experiencing minimal adverse effects.
Common (typically mild and transient):
- Injection site reactions (redness, itching, minor swelling)
- Headache, particularly during initial use
- Flushing or warmth sensation post-injection
- Mild water retention
- Increased hunger in some individuals
- Drowsiness, especially with evening doses
Less Common:
- Lightheadedness or dizziness
- Numbness or tingling in extremities
- Joint stiffness
Rare/Theoretical Concerns:
- Potential effects on glucose metabolism with long-term use
- Theoretical concerns regarding growth promotion in undiagnosed malignancies (applies to all GH-elevating compounds)
Most side effects diminish with continued use as the body adjusts. Starting with lower doses and gradually increasing can minimize initial discomfort.
Legal Status / FDA
Ipamorelin occupies a gray area in most jurisdictions. In the United States, it is not FDA-approved for any medical indication and is classified as a research chemical. It can be legally purchased for research purposes but is not approved for human consumption.
The FDA has issued warning letters to companies marketing peptides like ipamorelin for human use, and selling it as a dietary supplement or therapeutic agent is prohibited. However, possession for personal use is not explicitly criminalized in most U.S. states.
International Regulations:
In Australia, ipamorelin is classified as a Schedule 4 prescription-only substance, requiring a physician's prescription for legal acquisition. The UK classifies it similarly, restricting sale but not criminalizing possession.
Users should research their specific jurisdiction's regulations, as legal status varies internationally and continues to evolve.
Sports / WADA
The World Anti-Doping Agency (WADA) explicitly prohibits ipamorelin under Section S2 of the Prohibited List, which bans peptide hormones, growth factors, and related substances. This prohibition applies both in-competition and out-of-competition.
Athletes subject to drug testing — including those in Olympic sports, professional leagues, collegiate athletics, and many amateur organizations — face sanctions if ipamorelin or its metabolites are detected. Testing methods have become increasingly sophisticated, with detection windows extending several days post-administration.
Any competitive athlete should assume ipamorelin use will result in a positive test and subsequent penalties, which may include suspension, loss of titles, and career consequences.
Conclusion
Ipamorelin represents one of the most selective and well-tolerated growth hormone secretagogues available. Its ability to stimulate natural GH release without significantly impacting cortisol, prolactin, or appetite hormones distinguishes it from other peptides in its class. While not FDA-approved for human use, it has garnered significant interest among those seeking enhanced recovery, improved body composition, and anti-aging benefits.
The existing research supports its efficacy in elevating growth hormone levels with a favorable side effect profile. However, users should acknowledge the limitations of current evidence, the legal considerations in their jurisdiction, and the importance of sourcing from reputable suppliers. As with any bioactive compound, individual responses vary, and consultation with a knowledgeable healthcare provider is advisable.